Table 4.
Antifungal Therapy Prescribed and Duration of Combination Antifungal Therapy for Invasive Fungal Infection
| Type of IFI (n) | CAF With Liposomal Amphotericin B, No. of Episodes (%) | CAF With Micafungin, No. of Episodes (%) | CAF, Median (IQR), days |
|---|---|---|---|
| Proven (35) | Voriconazole: 12 (34.2) | Voriconazole: 5 (14.2) | 8 (5–13.5) |
| Micafungin: 6 (17.1) | Fluconazole: 1 (2.8) | ||
| Itraconazole: 4 (11.4) | Posaconazole: 1 (2.8) | ||
| Posaconazole: 4 (11.4) | Conventional amphotericin B: 1 (2.8) | ||
| Fluconazole: 1 (2.8) | |||
|
| |||
| Probable (11) | Voriconazole: 4 (36.3) | Voriconazole: 6 (54.5) | 6 (5.5–14) |
| Itraconazole: 1 (9) | |||
|
| |||
| Possible (26) | Voriconazole: 5 (19.2) | Voriconazole: 15 (57.6) | 5 (4–6.74) |
| Posaconazole: 3 (11.5) | Isavuconazole: 2 (7.7) | ||
| Fluconazole: 1 (3.8) | |||
CAF, Combination Antifungal Therapy